Ultra-Low-Pass Whole-Genome Sequencing of Circulating Tumor DNA Identifies Prognostic Markers in Hepatocellular Carcinoma
Ultra-low-pass whole-genome sequencing (ULP-WGS) of circulating tumor DNA (ctDNA) can provide clinically relevant information about tumor biology in patients with hepatocellular carcinoma (HCC) under systemic treatment. The presence of ctDNA and the loss of specific genomic regions (5q and 16q) were identified as independent predictors of worse prognosis in advanced HCC patients receiving systemic therapy. These findings highlight the potential of ULP-WGS in identifying patients with HCC who carry a worse prognosis.
Obese patients recovered as smoothly as normal-weight patients after robotic liver resection at experienced centers, according to a multinational study across 29 centers.
